Oppenheimer Reiterates Outperform on Achieve Life Sciences, Maintains $18 Price Target
Portfolio Pulse from Benzinga Newsdesk
Oppenheimer analyst Francois Brisebois reiterates an Outperform rating on Achieve Life Sciences (NASDAQ:ACHV) and maintains an $18 price target.
April 01, 2024 | 1:14 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Oppenheimer analyst Francois Brisebois reiterates an Outperform rating on Achieve Life Sciences and maintains an $18 price target.
The reiteration of an Outperform rating and the maintenance of an $18 price target by a reputable analyst like Francois Brisebois from Oppenheimer is likely to instill confidence among investors and could lead to a positive short-term impact on ACHV's stock price. Analyst ratings and price targets are significant indicators for investors, and a positive outlook from a well-regarded financial institution can contribute to bullish sentiment around the stock.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100